이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!
Caplin Point Laboratories 과거 수익 실적
과거 기준 확인 4/6
Caplin Point Laboratories은 연평균 18.8%의 비율로 수입이 증가해 온 반면, Pharmaceuticals 산업은 수입이 증가했으며, 연간 17%였습니다. 매출은 연평균 17.5%의 비율로 증가했습니다. Caplin Point Laboratories의 자기자본이익률은 19.7%이고 순이익률은 27%입니다.
주요 정보
18.8%
수익 성장률
18.7%
EPS 성장률
Pharmaceuticals 산업 성장 | 17.5% |
매출 성장률 | 17.5% |
자기자본 수익률 | 19.7% |
순이익 | 27.0% |
최근 수익 업데이트 | 31 Mar 2024 |
최근 과거 실적 업데이트
Recent updates
Caplin Point Laboratories (NSE:CAPLIPOINT) Strong Profits May Be Masking Some Underlying Issues
May 24Does Caplin Point Laboratories (NSE:CAPLIPOINT) Deserve A Spot On Your Watchlist?
May 04Caplin Point Laboratories Limited's (NSE:CAPLIPOINT) Low P/E No Reason For Excitement
Mar 07With EPS Growth And More, Caplin Point Laboratories (NSE:CAPLIPOINT) Makes An Interesting Case
Oct 24Why We Think The CEO Of Caplin Point Laboratories Limited (NSE:CAPLIPOINT) May Soon See A Pay Rise
Sep 15Caplin Point Laboratories (NSE:CAPLIPOINT) Will Pay A Larger Dividend Than Last Year At ₹2.50
Aug 11We Discuss Whether Caplin Point Laboratories Limited's (NSE:CAPLIPOINT) CEO Is Due For A Pay Rise
Sep 23Caplin Point Laboratories' (NSE:CAPLIPOINT) Shareholders Will Receive A Bigger Dividend Than Last Year
Sep 11Is Now The Time To Put Caplin Point Laboratories (NSE:CAPLIPOINT) On Your Watchlist?
Jul 22Caplin Point Laboratories (NSE:CAPLIPOINT) Is Increasing Its Dividend To ₹2.00
May 15A Look At The Intrinsic Value Of Caplin Point Laboratories Limited (NSE:CAPLIPOINT)
Jan 21Should You Be Adding Caplin Point Laboratories (NSE:CAPLIPOINT) To Your Watchlist Today?
Oct 20Caplin Point Laboratories (NSE:CAPLIPOINT) Is Increasing Its Dividend To ₹1.50
Sep 17Caplin Point Laboratories (NSE:CAPLIPOINT) Will Pay A Larger Dividend Than Last Year At ₹1.50
Sep 03Caplin Point Laboratories Limited's (NSE:CAPLIPOINT) Intrinsic Value Is Potentially 28% Above Its Share Price
Aug 27Is Caplin Point Laboratories (NSE:CAPLIPOINT) A Risky Investment?
Jun 12Estimating The Fair Value Of Caplin Point Laboratories Limited (NSE:CAPLIPOINT)
Apr 29Does Caplin Point Laboratories Limited (NSE:CAPLIPOINT) Have A Place In Your Dividend Portfolio?
Mar 24We Think Caplin Point Laboratories (NSE:CAPLIPOINT) Can Stay On Top Of Its Debt
Mar 11Do Caplin Point Laboratories's (NSE:CAPLIPOINT) Earnings Warrant Your Attention?
Feb 26What We Learned About Caplin Point Laboratories' (NSE:CAPLIPOINT) CEO Pay
Feb 14Caplin Point Laboratories Limited's (NSE:CAPLIPOINT) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
Feb 02Can You Imagine How Jubilant Caplin Point Laboratories' (NSE:CAPLIPOINT) Shareholders Feel About Its 105% Share Price Gain?
Jan 21Does This Valuation Of Caplin Point Laboratories Limited (NSE:CAPLIPOINT) Imply Investors Are Overpaying?
Jan 09Could The Caplin Point Laboratories Limited (NSE:CAPLIPOINT) Ownership Structure Tell Us Something Useful?
Dec 28Is It Worth Buying Caplin Point Laboratories Limited (NSE:CAPLIPOINT) For Its 0.5% Dividend Yield?
Dec 16We Think Caplin Point Laboratories (NSE:CAPLIPOINT) Can Stay On Top Of Its Debt
Dec 04Should You Be Adding Caplin Point Laboratories (NSE:CAPLIPOINT) To Your Watchlist Today?
Nov 21Here's What We Learned About The CEO Pay At Caplin Point Laboratories Limited (NSE:CAPLIPOINT)
Nov 08수익 및 비용 분석
수익 및 비용 분석
Caplin Point Laboratories 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.
수익 및 매출 내역
날짜 | 수익 | 수익 | G+A 비용 | R&D 비용 |
---|---|---|---|---|
31 Mar 24 | 16,941 | 4,571 | 1,436 | 0 |
31 Dec 23 | 16,318 | 4,376 | 1,430 | 632 |
30 Sep 23 | 15,683 | 4,179 | 1,408 | 632 |
30 Jun 23 | 15,157 | 3,947 | 1,396 | 0 |
31 Mar 23 | 14,683 | 3,763 | 1,371 | 632 |
31 Dec 22 | 14,182 | 3,532 | 1,314 | 593 |
30 Sep 22 | 13,724 | 3,307 | 1,262 | 593 |
30 Jun 22 | 13,153 | 3,140 | 1,210 | 0 |
31 Mar 22 | 12,710 | 2,998 | 1,154 | 593 |
31 Dec 21 | 12,099 | 2,872 | 1,110 | 537 |
30 Sep 21 | 11,581 | 2,767 | 1,071 | 537 |
30 Jun 21 | 11,217 | 2,586 | 1,034 | 0 |
31 Mar 21 | 10,624 | 2,423 | 1,026 | 537 |
31 Dec 20 | 9,986 | 2,248 | 952 | 530 |
30 Sep 20 | 9,524 | 2,189 | 874 | 530 |
30 Jun 20 | 9,107 | 2,193 | 780 | 0 |
31 Mar 20 | 8,640 | 2,150 | 678 | 530 |
31 Dec 19 | 8,356 | 2,159 | 617 | 282 |
30 Sep 19 | 7,664 | 2,032 | 557 | 282 |
30 Jun 19 | 6,948 | 1,894 | 512 | 0 |
31 Mar 19 | 6,490 | 1,766 | 471 | 282 |
31 Dec 18 | 6,048 | 1,621 | 449 | 237 |
30 Sep 18 | 5,874 | 1,538 | 431 | 237 |
30 Jun 18 | 5,628 | 1,459 | 417 | 0 |
31 Mar 18 | 5,399 | 1,448 | 391 | 237 |
31 Dec 17 | 5,145 | 1,430 | 367 | 141 |
30 Sep 17 | 4,757 | 1,297 | 352 | 141 |
30 Jun 17 | 4,401 | 1,165 | 322 | 0 |
31 Mar 17 | 4,016 | 956 | 321 | 141 |
31 Dec 16 | 3,655 | 783 | 300 | 54 |
30 Sep 16 | 3,420 | 703 | 274 | 54 |
30 Jun 16 | 3,238 | 619 | 258 | 54 |
31 Mar 16 | 3,088 | 584 | 240 | 54 |
31 Dec 15 | 2,906 | 535 | 298 | 67 |
30 Sep 15 | 2,722 | 465 | 283 | 60 |
30 Jun 15 | 2,518 | 410 | 203 | 59 |
31 Mar 15 | 2,296 | 353 | 233 | 53 |
31 Dec 14 | 2,074 | 318 | 220 | 42 |
30 Sep 14 | 1,893 | 305 | 204 | 33 |
30 Jun 14 | 1,731 | 258 | 190 | 21 |
31 Mar 14 | 1,643 | 204 | 166 | 4 |
31 Dec 13 | 1,517 | 167 | 149 | 0 |
30 Sep 13 | 1,408 | 125 | 137 | 0 |
양질의 수익: CAPLIPOINT 의 비현금 수입 수준이 높습니다.
이익 마진 증가: CAPLIPOINT 의 현재 순이익 이익률 (27%) 작년보다 높습니다 (25.6%).
잉여현금흐름 대 수익 분석
과거 수익 성장 분석
수익추이: CAPLIPOINT 의 수입은 지난 5년 동안 매년 18.8% 씩 증가했습니다.
성장 가속화: 지난 1년간 CAPLIPOINT 의 수익 증가율( 21.5% )은 연간 평균( 18.8% 초과합니다. ).
수익 대 산업: 지난 1년간 CAPLIPOINT 수익 증가율( 21.5% )은 Pharmaceuticals 업계 18% 초과했습니다.
자기자본 수익률
높은 ROE: CAPLIPOINT 의 자본 수익률( 19.7% )은 낮음으로 간주됩니다.